Trial Growth in Latin America Raises Demand for Specialist Insurance Brokerage
Clinical research insurance brokerage services in Latin America are gaining stronger relevance as sponsors, CROs and medical device developers expand trial activity across the region. Latin America offers patient access, experienced investigators and competitive research costs, but sponsors also need insurance programs that satisfy local regulators and ethics committees before studies can begin.
The region’s clinical research market is expanding. One 2026 market estimate values the Latin America clinical trials market at USD 4.44 billion in 2026 and projects it to reach USD 11.86 billion by 2036, at a CAGR of 10.32 percent. Another outlook expects the Latin America pharmaceutical CRO market to reach USD 5.48 billion by 2033, with a CAGR of 7 percent from 2026 to 2033.
This growth increases the need for brokerage support because clinical trial insurance is not a generic liability purchase. A policy must match the study protocol, participant risk profile, country requirements, investigator obligations and sponsor structure. A sponsor running trials in Brazil, Mexico or Argentina may face different documentation expectations from each authority or ethics committee.
The regulatory landscape of Latin America is also divided. A 2026 regional regulatory guide lists different approval timelines across countries, including 60 to 90 days for ANVISA in Brazil, 42 to 62 days for ANMAT in Argentina, 120 to 280 days for INVIMA in Colombia and 180 to 220 days for COFEPRIS in Mexico.
That variation makes brokerage coordination more valuable. The sponsor requires the issuance of the policy in the correct jurisdiction, along with the right limitations, insured and translation where necessary. This means that there may be a delay in getting acceptable evidence of the policy.
Specialist brokers also help sponsors understand coverage language. Clinical trial insurance in Latin America may need to address participant injury, extracontractual civil liability, defense costs, policy period, retroactive dates and deductible structure. Bioaccess notes that many authorities and ethics committees require policies or certified translations in Spanish and that sponsors need brokers familiar with country-specific documentation requirements.
The business risk is practical. While a multinational corporation may be covered under a master policy, there could be a need for certificates or admitted policies from local committees. A broker that understands both global programs and local evidence requirements can prevent avoidable back-and-forth during startup.
Clinical research insurance brokerage in Latin America is moving toward being trial-startup facilitators. Their success will depend on how effective they are at helping the sponsor get appropriate coverage, while minimizing insurance delays in the region’s increasing clinical research field.
